Harwin Peter Evan's Form 4 filing
Dianthus Therapeutics, Inc.DNTH · filed Sep 21, 2023
- Accession no.
- 0000899243-23-019370
- Filed
- Sep 21, 2023, 4:23 PM ET
- Trade date
- Sep 19, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $396.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director, 10% Owner |
| Fairmount Funds Management LLCCIK 0001802528 | Director, 10% Owner |
| Kiselak TomasCIK 0001830177 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2023 | Common Stock | PPurchaseAcquired | +30,000 | $13.20 | +$396,000 | 1,873,833 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Fairmount, Fund I, Fund II and Fairmount SPV III, LLC may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.